Increase in anti-tuberculosis drug resistance in Botswana

Results from the fourth National Drug Resistance Survey

Heather J. Menzies, G. Moalosi, V. Anisimova, V. Gammino, C. Sentle, Marcus A. Bachhuber, E. Bile, K. Radisowa, O. Kachuwaire, J. Basotli, T. Maribe, R. Makombe, J. Shepherd, B. Kim, T. Samandari, S. El-Halabi, J. Chirenda, K. P. Cain

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

SETTING: Although approximately 0.5 million cases of multidrug-resistant tuberculosis (MDR-TB) occur globally each year, surveillance data are limited. Botswana is one of the few high TB burden countries to have carried out multiple anti-tuberculosis drug resistance surveys (in 1995-1996, 1999 and 2002). OBJECTIVE: In 2007-2008, we conducted the fourth national survey of anti-tuberculosis drug resistance in Botswana to assess anti-tuberculosis drug resistance, including trends over time. In the previous survey, 0.8% (95%CI 0.4-1.5) of new patients and 10.4% (95%CI 5.6-17.3) of previously treated patients had MDR-TB. DESIGN: During the survey period, eligible specimens from all new sputum-smear positive TB patients and from all TB patients with history of previous antituberculosis treatment underwent mycobacterial culture and anti-tuberculosis drug susceptibility testing (DST). RESULTS: Of 924 new TB patients and 137 with previous anti-tuberculosis treatment with DST results, respectively 23 (2.5%, 95%CI 1.6-3.7) and 9 (6.6%, 95%CI 3.3-11.7) had MDR-TB. The proportion of new TB patients with MDR-TB has tripled in Botswana since the previous survey. CONCLUSION: Combatting drug-resistant TB will require the scale-up of MDR-TB diagnosis and treatment to prevent the transmission of MDR-TB and strengthening of general TB control to prevent the emergence of resistance.

Original languageEnglish (US)
Pages (from-to)1026-1033
Number of pages8
JournalInternational Journal of Tuberculosis and Lung Disease
Volume18
Issue number9
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Botswana
Multidrug-Resistant Tuberculosis
Drug Resistance
Tuberculosis
Pharmaceutical Preparations
Sputum
Surveys and Questionnaires
Therapeutics

Keywords

  • Drug resistance
  • Surveillance
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases
  • Medicine(all)

Cite this

Increase in anti-tuberculosis drug resistance in Botswana : Results from the fourth National Drug Resistance Survey. / Menzies, Heather J.; Moalosi, G.; Anisimova, V.; Gammino, V.; Sentle, C.; Bachhuber, Marcus A.; Bile, E.; Radisowa, K.; Kachuwaire, O.; Basotli, J.; Maribe, T.; Makombe, R.; Shepherd, J.; Kim, B.; Samandari, T.; El-Halabi, S.; Chirenda, J.; Cain, K. P.

In: International Journal of Tuberculosis and Lung Disease, Vol. 18, No. 9, 01.09.2014, p. 1026-1033.

Research output: Contribution to journalArticle

Menzies, HJ, Moalosi, G, Anisimova, V, Gammino, V, Sentle, C, Bachhuber, MA, Bile, E, Radisowa, K, Kachuwaire, O, Basotli, J, Maribe, T, Makombe, R, Shepherd, J, Kim, B, Samandari, T, El-Halabi, S, Chirenda, J & Cain, KP 2014, 'Increase in anti-tuberculosis drug resistance in Botswana: Results from the fourth National Drug Resistance Survey', International Journal of Tuberculosis and Lung Disease, vol. 18, no. 9, pp. 1026-1033. https://doi.org/10.5588/ijtld.13.0749
Menzies, Heather J. ; Moalosi, G. ; Anisimova, V. ; Gammino, V. ; Sentle, C. ; Bachhuber, Marcus A. ; Bile, E. ; Radisowa, K. ; Kachuwaire, O. ; Basotli, J. ; Maribe, T. ; Makombe, R. ; Shepherd, J. ; Kim, B. ; Samandari, T. ; El-Halabi, S. ; Chirenda, J. ; Cain, K. P. / Increase in anti-tuberculosis drug resistance in Botswana : Results from the fourth National Drug Resistance Survey. In: International Journal of Tuberculosis and Lung Disease. 2014 ; Vol. 18, No. 9. pp. 1026-1033.
@article{d38985b8506f4b9497a5775e8d456f4c,
title = "Increase in anti-tuberculosis drug resistance in Botswana: Results from the fourth National Drug Resistance Survey",
abstract = "SETTING: Although approximately 0.5 million cases of multidrug-resistant tuberculosis (MDR-TB) occur globally each year, surveillance data are limited. Botswana is one of the few high TB burden countries to have carried out multiple anti-tuberculosis drug resistance surveys (in 1995-1996, 1999 and 2002). OBJECTIVE: In 2007-2008, we conducted the fourth national survey of anti-tuberculosis drug resistance in Botswana to assess anti-tuberculosis drug resistance, including trends over time. In the previous survey, 0.8{\%} (95{\%}CI 0.4-1.5) of new patients and 10.4{\%} (95{\%}CI 5.6-17.3) of previously treated patients had MDR-TB. DESIGN: During the survey period, eligible specimens from all new sputum-smear positive TB patients and from all TB patients with history of previous antituberculosis treatment underwent mycobacterial culture and anti-tuberculosis drug susceptibility testing (DST). RESULTS: Of 924 new TB patients and 137 with previous anti-tuberculosis treatment with DST results, respectively 23 (2.5{\%}, 95{\%}CI 1.6-3.7) and 9 (6.6{\%}, 95{\%}CI 3.3-11.7) had MDR-TB. The proportion of new TB patients with MDR-TB has tripled in Botswana since the previous survey. CONCLUSION: Combatting drug-resistant TB will require the scale-up of MDR-TB diagnosis and treatment to prevent the transmission of MDR-TB and strengthening of general TB control to prevent the emergence of resistance.",
keywords = "Drug resistance, Surveillance, Tuberculosis",
author = "Menzies, {Heather J.} and G. Moalosi and V. Anisimova and V. Gammino and C. Sentle and Bachhuber, {Marcus A.} and E. Bile and K. Radisowa and O. Kachuwaire and J. Basotli and T. Maribe and R. Makombe and J. Shepherd and B. Kim and T. Samandari and S. El-Halabi and J. Chirenda and Cain, {K. P.}",
year = "2014",
month = "9",
day = "1",
doi = "10.5588/ijtld.13.0749",
language = "English (US)",
volume = "18",
pages = "1026--1033",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "9",

}

TY - JOUR

T1 - Increase in anti-tuberculosis drug resistance in Botswana

T2 - Results from the fourth National Drug Resistance Survey

AU - Menzies, Heather J.

AU - Moalosi, G.

AU - Anisimova, V.

AU - Gammino, V.

AU - Sentle, C.

AU - Bachhuber, Marcus A.

AU - Bile, E.

AU - Radisowa, K.

AU - Kachuwaire, O.

AU - Basotli, J.

AU - Maribe, T.

AU - Makombe, R.

AU - Shepherd, J.

AU - Kim, B.

AU - Samandari, T.

AU - El-Halabi, S.

AU - Chirenda, J.

AU - Cain, K. P.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - SETTING: Although approximately 0.5 million cases of multidrug-resistant tuberculosis (MDR-TB) occur globally each year, surveillance data are limited. Botswana is one of the few high TB burden countries to have carried out multiple anti-tuberculosis drug resistance surveys (in 1995-1996, 1999 and 2002). OBJECTIVE: In 2007-2008, we conducted the fourth national survey of anti-tuberculosis drug resistance in Botswana to assess anti-tuberculosis drug resistance, including trends over time. In the previous survey, 0.8% (95%CI 0.4-1.5) of new patients and 10.4% (95%CI 5.6-17.3) of previously treated patients had MDR-TB. DESIGN: During the survey period, eligible specimens from all new sputum-smear positive TB patients and from all TB patients with history of previous antituberculosis treatment underwent mycobacterial culture and anti-tuberculosis drug susceptibility testing (DST). RESULTS: Of 924 new TB patients and 137 with previous anti-tuberculosis treatment with DST results, respectively 23 (2.5%, 95%CI 1.6-3.7) and 9 (6.6%, 95%CI 3.3-11.7) had MDR-TB. The proportion of new TB patients with MDR-TB has tripled in Botswana since the previous survey. CONCLUSION: Combatting drug-resistant TB will require the scale-up of MDR-TB diagnosis and treatment to prevent the transmission of MDR-TB and strengthening of general TB control to prevent the emergence of resistance.

AB - SETTING: Although approximately 0.5 million cases of multidrug-resistant tuberculosis (MDR-TB) occur globally each year, surveillance data are limited. Botswana is one of the few high TB burden countries to have carried out multiple anti-tuberculosis drug resistance surveys (in 1995-1996, 1999 and 2002). OBJECTIVE: In 2007-2008, we conducted the fourth national survey of anti-tuberculosis drug resistance in Botswana to assess anti-tuberculosis drug resistance, including trends over time. In the previous survey, 0.8% (95%CI 0.4-1.5) of new patients and 10.4% (95%CI 5.6-17.3) of previously treated patients had MDR-TB. DESIGN: During the survey period, eligible specimens from all new sputum-smear positive TB patients and from all TB patients with history of previous antituberculosis treatment underwent mycobacterial culture and anti-tuberculosis drug susceptibility testing (DST). RESULTS: Of 924 new TB patients and 137 with previous anti-tuberculosis treatment with DST results, respectively 23 (2.5%, 95%CI 1.6-3.7) and 9 (6.6%, 95%CI 3.3-11.7) had MDR-TB. The proportion of new TB patients with MDR-TB has tripled in Botswana since the previous survey. CONCLUSION: Combatting drug-resistant TB will require the scale-up of MDR-TB diagnosis and treatment to prevent the transmission of MDR-TB and strengthening of general TB control to prevent the emergence of resistance.

KW - Drug resistance

KW - Surveillance

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84906700573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906700573&partnerID=8YFLogxK

U2 - 10.5588/ijtld.13.0749

DO - 10.5588/ijtld.13.0749

M3 - Article

VL - 18

SP - 1026

EP - 1033

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 9

ER -